Latest News & Updates
OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.
The generics and specialty manufacturer Mylan has recalled several chemotherapy agents, including gemcitabine, carboplatin, methotrexate, and cytarabine, due to the presence of visible foreign particulates.
The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
The FDA has approved second-line ramucirumab in combination with FOLFIRI as a treatment for patients with metastatic colorectal cancer following progression an upfront bevacizumab-containing regimen.
The FDA has updated the label for pomalidomide plus low-dose dexamethasone to include data from the phase III MM-003 study.
Latest Peer Exchange Discussions
Robert I. Haddad, MD, discusses strategies for managing recurrent metastatic thyroid cancer. View Now
In this segment, Roy S. Herbst, MD, PhD, and Anne S. Tsao, MD, explore the use of targeted therapy in non-small cell lung cancer. View Now
In this segment, Ivy Altomare, MD, and Howard A. Liebman, MD, explain current treatment practices of individuals with idiopathic thrombocytopenic purpura. View Now
Most Popular Right Now
Online CME Activities